A genome epidemiological study of SARS-CoV-2 introduction into Japan

Tsuyoshi Sekizuka^{1*}, Kentaro Itokawa¹, Masanori Hashino¹, Tetsuro Kawano-Sugaya¹, Rina Tanaka¹, Koji Yatsu¹, Asami Ohnishi², Keiko Goto³, Hiroyuki Tsukagoshi⁴, Hayato Ehara⁵, Kenji Sadamasu⁶, Masakatsu Taira⁷, Shinichiro Shibata⁸, Ryohei Nomoto⁹, Satoshi Hiroi¹⁰, Miho Toho¹¹, Tomoe Shimada¹², Tamano Matsui¹², Tomimasa Sunagawa¹², Hajime Kamiya¹², Yuichiro Yahata¹², Takuya Yamagishi¹², Motoi Suzuki¹², Takaji Wakita¹³, and Makoto Kuroda^{1*} and COVID-19 Genomic Surveillance Network in Japan.

- 1, Pathogen Genomics Center, National Institute of Infectious Diseases, Tokyo, Japan.
- 2, Sapporo City Institute of Public Health.
- 3, Ibaraki Prefectural Institute of Public Health, Ibaraki, Japan.
- 4, Gunma Prefectural Institute of Public Health and Environmental Sciences, Gunma, Japan.
- 5, Saitama Prefectural Institute of Public Health, Saitama, Japan.
- 6, Department of Microbiology, Tokyo Metropolitan Institute of Public Health, Tokyo, Japan.
- 7, Division of Virology and Medical Zoology, Chiba Prefectural Institute of Public Health, Chiba, Japan.
- 8, Microbiology Department, Nagoya City Public Health Research Institute, Aichi, Japan.
- 9, Department of Infectious Diseases, Kobe Institute of Health, Kobe, Hyogo, Japan.
- 10, Division of Microbiology, Osaka Institute of Public Health, Osaka, Japan.
- 11, Fukui Prefectural Institute of Public Health and Environmental Science, Fukui, Japan.
- 12, Infectious Disease Surveillance Center, National Institute of Infectious Diseases, Tokyo, Japan.
- 13, National Institute of Infectious Diseases, Tokyo, Japan.

Correspondence:

Makoto Kuroda, PhD

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

34 Director, Pathogen Genomics Center, National Institute of Infectious Diseases.
35 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8640, Japan.
36 Phone: +[81]-3-5285-1111
37 E-mail: makokuro@niid.go.jp
38
39

40 **Abstract**

41 **Background:**

42 After the first case of COVID-19 in Japan on 15 January 2020, multiple nationwide
 43 COVID-19 clusters were identified by the end of February. The Japanese government
 44 focused on mitigating emerging COVID-19 clusters by conducting active nationwide
 45 epidemiological surveillance. However, an increasing number of cases appeared until
 46 early April, many with unclear infection routes exhibiting no recent history of travel
 47 outside Japan. We aimed to evaluate the severe acute respiratory syndrome coronavirus
 48 2 (SARS-CoV-2) genome sequences from COVID-19 cases until early April and
 49 characterise the genealogical networks to demonstrate possible routes of spread in
 50 Japan.

51 **Methods:**

52 Nasopharyngeal specimens were collected from patients and a quantitative reverse
 53 transcription polymerase chain reaction testing for SARS-CoV-2 was performed. Positive
 54 RNA samples were subjected whole genome sequencing and a haplotype network
 55 analysis was performed.

56 **Findings:**

57 Some of the primary clusters identified during January and February in Japan directly
 58 descended from Wuhan-Hu-1-related isolates in China and other distinct clusters.
 59 Clusters were almost contained until mid-March; the haplotype network analysis
 60 demonstrated that COVID-19 cases from late March through early April may have caused
 61 an additional large cluster related to the outbreak in Europe, leading to additional spread
 62 within Japan. National self-restraint during February was effective in mitigating the
 63 COVID-19 spread, but late action on stopping immigration and declaring national
 64 emergency in Japan might be involved in the later increase in cases.

65 **Interpretation:**

66 Genome surveillance suggested that at least two distinct SARS-CoV-2 introductions
67 from China and other countries occurred.

68 **Funding:** Japan Agency for Medical Research and Development.

69

70

71 Introduction

72 The initial coronavirus disease 2019 (COVID-19) outbreak occurred in Wuhan, China
 73 in late December 2019. It was caused by a new strain of beta coronavirus, known as the
 74 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ¹⁻³. After the
 75 identification of the first patient with COVID-19 in Japan on 15 January 2020, multiple
 76 local COVID-19 clusters were identified nationwide by the end of February. The
 77 Japanese government focused on identifying and mitigating emerging COVID-19
 78 clusters before they could spread further. In an effort to contain these clusters and limit
 79 the number of new cases, active, nationwide epidemiological surveillance of each
 80 cluster was conducted in order to identify the close contacts of existing patients with
 81 COVID-19. Japan has sustained a moderate spread by focusing on COVID-19 outbreak
 82 clusters; however, an ever-increasing number of COVID-19 cases appeared until early
 83 April, which made it difficult to identify all infection routes.

84 Although some of the COVID-19 clusters were successfully contained, the number of
 85 cases continued to increase. As of 16 April, the Japanese government declared a
 86 nationwide state of emergency in view of the worsening spread. To support the ongoing
 87 epidemiological surveillance, we collaborated with the local public health institutes in
 88 Japan (Supplementary Table S1) and conducted a whole genome sequencing of SARS-
 89 CoV-2. Our goal was to apply genomic epidemiology to predict potential routes of
 90 infection within or between clusters ⁴. Thus far, multiple studies have been conducted to
 91 demonstrate the COVID-19 spread under nationwide and global comparative genome
 92 surveillance; as of 2 June, there were already 33,483 complete genomes publicly
 93 available in the Global Initiative on Sharing All Influenza Data (GISAID) platform ⁵.
 94 Some detailed reports have been conducted to highlight regional specific clusters and its
 95 intra- and international spreads in the US ⁶, UK ⁷, Hungary ⁸, Australia ⁹, Denmark ¹⁰,
 96 Iceland ¹¹, and California ¹²

97 In this study, we aimed to evaluate viral genome sequences from COVID-19 cases until
 98 early April and characterise the genealogical networks to demonstrate possible routes of
 99 spread in Japan.

100 Methods

Ethical approval and consent to participate

The study protocol was approved by the National Institute of Infectious Diseases in Japan (Approval No. 1091). It was conducted according to the principles of the Declaration of Helsinki, in compliance with the Law Concerning the Prevention of Infections and Medical Care for Patients of Infections of Japan. The ethical committee waived the need for written consent since the study involved the viral genome sequencing. The personal data related to the clinical information were anonymised, and our procedure is to not request written consent for all patients with COVID-19.

Clinical specimens and reverse transcription polymerase chain reaction (RT-qPCR) testing for COVID-19

Nasopharyngeal specimens were collected from patients and a quantitative RT-qPCR testing for SARS-CoV-2^{13,14} was performed at local public health institutes in Japan (Supplementary Table S1). The positive RNA samples were subjected to whole genome sequencing.

Whole genome sequencing of SARS-CoV-2

Whole genome sequences of SARS-CoV-2 were obtained by means of the PrimalSeq protocol for enriching the cDNA of the SARS-CoV-2 genome using multiplex RT-PCR, as proposed by the Wellcome Trust ARTIC Network¹⁵. We found two amplicons that regularly showed low to zero coverage due to primer dimerization as described by Itokawa et al.¹⁶. Therefore, we have modified the ARTIC Network's protocol for SARS-CoV-2 genome sequencing by replacing some primers for the multiplex PCR¹⁷. The PCR products in pool 1 and 2 from the same clinical sample were pooled, purified, and subjected to Illumina library construction using a QIAseq FX DNA Library Kit (QIAGEN, Hilden Germany). NextSeq 500 platform (Illumina, San Diego, CA) was used for sequencing the indexed libraries. The next-generation sequencing (NGS) reads were mapped to the SARS-CoV-2 Wuhan-Hu-1 reference genome sequence (29.9 kb ss-RNA; GenBank ID: MN908947), resulting in the specimen-specific SARS-CoV-2 genome

sequence by fully mapping on the reference. These mapped reads of SARS-CoV-2 sequences were assembled using A5-miseq v.20140604¹⁸ to determine the full genome sequence (Supplementary Table S2). The single nucleotide variations (SNV) sites and marked heterogeneity were extracted by the read-mapping at $\geq 10\times$ depth and from 99 - 29796 nt region of Wuhan-Hu-1 genome sequence.

Comparative genome sequence and SNV analyses

The nearly full-length genome sequence (≥ 29 kb) of SARS-CoV-2 was retrieved from the GISAID EpiCoV database in 28 April 2020, followed by multiple alignment using MAFFT v7.222¹⁹. The poorly aligned regions in 5' and 3' end were trimmed; we determined that the core regions were from 99 to 29796 nt position against Wuhan-Hu-1 genome sequences (GISAID ID, EPI_ISL_402125; GenBank ID, MN908947.3). Gap-containing sequences in the core region were excluded; sequences of 2,887 isolates in GISAID database were eventually used in subsequent analyses (isolate collection by 16 April 2020; submitted to GISAID by 27 April 2020; Supplementary Table S3). The genome sequences were aligned using MAFFT software together with sequences retrieved from databases, followed by extraction of SNV sites. The network analysis was performed using TCS 1.21²⁰.

Network graph visualization

We had applied various visualization software for network graph visualization such as Network, PopART, TCS, and Cytoscape. Nevertheless, all of the currently available resources have not been suitable for the spatiotemporal dissection of SARS-CoV-2 genomic epidemiology and substantial on-site cluster eradication. Thus, we developed Haplotype Explorer software to visualise the spatiotemporal pattern of SARS-CoV-2 infections based on network graphs (<https://github.com/TKSjp/HaplotypeExplorer>). Haplotype Explorer allows for the analysis of network graphs spatiotemporally by searching and filtering nodes interactively according to meta-data (e.g., collection date, location, and accession number). Over 100 network graph images were captured daily from the initial detection of SARS-CoV-2 (Wuhan-Hu-1; 31 December 2019) to 16 April,

the day when Japan declared a national emergency. Interactive network file (html file; Supplementary dataset 1) and the movie (mp4 file; Supplementary dataset 2) are available.

Comparison between outdoor activity and number of cases in Japan, the USA, and the UK

We explored the relationships between outdoor activity, daily COVID-19 cases, and local stay-at-home/shelter-in-place order/self-restraint campaigns in Japan, the USA (for New York city and San Francisco Bay area), and the UK. The data shows population mobility normalised to the value of 13 January 2020, which were retrieved from the COVID-19 mobility report provided by Apple (the data is available for a limited time only)²¹. The values for walking were plotted for the three mentioned countries. Subsequently, we plotted the mobility graph with daily and total COVID-19 cases, which were provided by the National Institute of Infectious Diseases (currently the only Japanese data available)²², Coronavirus Data in the United States (provided by New York Times)²³, and Coronavirus Source Data²⁴.

Role of the funding source

The funding agencies had no role in the study design, data collection or analysis, decision to publish, or manuscript preparation.

Results and Discussion

The nearly full-length genome sequences (≥ 29 kb, 2,887 entries) of SARS-CoV-2 were retrieved from the GISAID EpiCoV database (collection by April 16, 2020; submitted by April 27, 2020)⁵. We determined the full genome sequences using 435 clinical specimens in Japan collected until April 6, followed by performing a maximum-likelihood (ML) phylogenetic analysis using genome-wide SNVs to trace potential infection routes (Fig. 1). After the identification of the first COVID-19 case in Japan on 15 January 2020, multiple local COVID-19 clusters were observed. The genome sequences of Japanese isolates were assigned based on phylogeny to China isolates from late February, but nationwide dissemination seemed to already be present based on the ML phylogeny (Fig. 1). At least 4 or 5 main clusters are observed on the ML phylogeny, but this was not

always adequately explained by the field epidemiological studies performed by local public health centres about the patient's information such as nationality, being a Wuhan returnee, and travel history.

Although phylogenetic trees are widely used for summarizing genealogies, one should avoid a naïve interpretation of those results since the slow rate of SARS-CoV-2 evolution and sampling bias of genomes could often lead to spurious conclusions²⁵. In order to decode the genealogies of the whole SARS-CoV-2 genome, we performed a haplotype network analysis describing ancestral relationships among the aforementioned genomic data sets and Wuhan-Hu-1 (GISAID ID, EPI_ISL_402125; GenBank ID, MN908947.3) as a potential most recent common ancestral (Fig 2).

Some of the primary clusters identified through January and February in Japan (2 red closed circles and magenta frames in Fig. 2) directly descended from the haplotype which was mostly seen in Wuhan-Hu-1-related isolates from China. Three other distinct clusters (additional 2 red closed circles and yellow frames in Fig. 2) were observed after the first introduction of Chinese isolates. Those four clusters of COVID-19 infections were assumed to be directly originated from the primary wave which occurred in China. Those clusters seemed to have been almost contained through the implementation of active surveillance in Japan until mid-March.

In contrast, the number of COVID-19 cases increased rapidly across Europe and North America during early March (right half of Fig. 2), indicating a pandemic was occurring. Concurrently, many sporadic COVID-19 cases were detected in Japan from the end of March through early April. The haplotype network analysis demonstrated that an additional large cluster (red closed circles and cyan frames in Fig 2) closely related to the outbreak in Europe (originating in China or other countries) was predominantly observed in Japan during early April, suggesting that they could have caused the increased spread within Japan.

Analysis of whole genome sequences provides information that is useful for tracing the spread of infection using genome-wide SNVs among clusters. To elucidate which Japan political decisions (Fig. 3A, and Supplementary Table S4) and activities were effectively

involved in the introduction of specific SARS-CoV-2 lineages, we characterised daily COVID-19 case reports and a mobility index of people inferred from iPhone tracking (Fig. 3B) in Japan, USA, and UK before and after the self-restraint campaign.

During the primary wave from China, international airports investigated potential patients with COVID-19 using the keywords “Wuhan, Hubei, Zhejiang, and China” in early February (Fig. 3A), and local public health centres were able to identify patients likely to be infected with COVID-19 and their close contacts within location-specific clusters by conducting active epidemiological surveillance. After the end of February, a national self-restraint was requested in Japan, leading to significant reductions in activity observed after the self-restraint was implemented. Although the situation in Japan had begun to improve around mid-March, a large number of new patients with COVID-19 were diagnosed, many of whom with unclear infection routes. Tracing the infection routes was difficult because some Japanese cases had no recent history of travel to China or any other country outside Japan.

During the national holidays from 20-22 March, a part of the population left their homes to visit the cherry blossoms, which possibly increased mobility (Fig. 3B). It was speculated that such a partial increase in activity at that time might have allowed for a resurgence of the remaining lineage from the first introduction which had previously circulated. The SARS-CoV-2 haplotype network analysis, however, suggested that the second wave of COVID-19 cases in late March had a distinct origin from the first wave lineage. The lineage of the second wave could have been imported by the returnees or travellers from Europe, North America, or other countries²⁶ (see the image in cyan frame in Fig. 2), but not by the remaining Wuhan lineage. Considering the increasing COVID-19 cases in Europe and the detection of imported cases in Japan, the Japanese government decided to stop immigration from Europe in 27 March (Fig. 3A).

On the other hand, increased mobility in the USA and UK continued through early March, possibly leading to a sharp increase in COVID-19 cases from mid-March (Fig. 3B). Intriguingly, activity in the San Francisco Bay area slowed down earlier than in New York; the additional 3 days taken by New York to implement stay-at-home/shelter-in-place orders compared to San Francisco may explain the mitigated COVID-19 spread in

257 San Francisco.

258

259 **Conclusions**

260 This genome surveillance study suggested that at least two distinct SARS-CoV-2
 261 introductions from China and other subsequent countries, including some in Europe, were
 262 detected. To mitigate the next wave of COVID-19 in Japan, it is necessary to formulate a
 263 more efficient containment strategy using real-time genome surveillance supporting
 264 epidemiological field investigations and highlight potential infection linkages.

265

266

267

Data Availability Statement

The new sequences have been deposited in Global Initiative on Sharing All Influenza Data (GISAID) with accession IDs EPI_ISL_479792 to EPI_ISL_480227 (Table S2).

Funding

This study was supported by a Grant-in Aid from the Japan Agency for Medical Research and Development (AMED) under Grant number JP20fk0108103, JP19fk0108103 and JP19fk0108104.

Acknowledgments

We sincerely thank the COVID-19 Genomic Surveillance Network in Japan (Supplementary Table S1) for the collection and transportation of clinical specimens. We are particularly grateful to the staff of the National Institute of Infectious Diseases, Field Epidemiology Training Program (FETP) team; the Ministry of Health, Labor and Welfare; and local governments for their assistance with administrative matters, field investigations, data collection, and laboratory testing.

We would like to thank all researchers who have kindly deposited and shared genomic data on GISAID. A table with genome sequence acknowledgments can be found in Supplementary Table S3.

Author Contributions

TS1, KI, WT, and MK designed and organised the genome study. AO, KG, HT, HE, KS, MT, SS, RN, SH, MT, and COVID-19 Genomic Surveillance Network in Japan (Table S1) performed the laboratory detection. RT and MH performed the genome sequencing, and TS1, KI, TKS and KY performed the genome analysis. TS2, TM, TS3, HK, YY, TY, and MS contributed to the field epidemiological study. MK wrote the manuscript.

296

297 **Declaration of interests**

298 The authors declare that the research was conducted in the absence of any commercial or
299 financial relationships that could be construed as a potential conflict of interest.

300

301 **Supplementary Table S1**

302 Collaboration with local public health institutes in COVID-19 Genomic Surveillance
303 Network in Japan.

304 **Supplementary Table S2**

305 Summary of NGS reads and in silico data analysis.

306 **Supplementary Table S3**

307 All GISAID-available SARS-CoV-2 genomes (n = 2,887).

308 **Supplementary Table S4**

309 Japanese immigration restriction programs.

310 **Supplementary dataset 1**

311 Interactive genomic network file (html format).

312 **Supplementary dataset 2**

313 Genomic network movie file (mp4 format).

314

315

Figure legends

Fig. 1. A maximum-likelihood phylogenetic analysis using SARS-CoV-2 genome sequences

In total, 2,212 SNVs were detected in 3,322 isolates, including Japanese isolates ($n = 435$). The maximum-likelihood phylogenetic tree was constructed using iqtree version 2.0.5 and Wuhan-Hu-1 (GISAID ID: EPI_ISL_402125) as an outgroup reference that is located on the centre point of the radial tree for tree rooting. The geographic and sample information are described in the colour schemes on the outer slot of the phylogenetic tree. The cluster of remarkable outbreaks in Japan are highlighted in bright red.

Fig. 2. Haplotype network analysis using genome-wide single-nucleotide variations of worldwide SARS-CoV-2 isolates.

A) Whole-genome sequences of SARS-CoV-2 isolates in Japan (n = 435) were compared to all GISAID-available SARS-CoV-2 genomes (n = 2,887, updated on 16 April 2020) using TCS network analysis. SARS-CoV-2 disseminating from Wuhan City, China, at the end of December 2019 (one of the potential origins of Wuhan-Hu-1) is plotted at the centre of the haplotype network. B) Three plots of time-series cumulative COVID-19 cases were highlighted in each enclosed square to visualise the increasing incident COVID-19 cases.

Fig. 3. Mobility index (walking) of people and daily COVID-19 cases in Japan, the United Kingdom, New York city, and San Francisco Bay area.

A) Timeline of political decisions for the COVID-19 quarantine and national actions in Japan (see also Supplementary Table S4). B) Mobility index of people and daily COVID-19 cases in Japan, the UK, and the USA (New York city and San Francisco Bay Area). Solid lines indicate mobility index of people inferred from map application usages given by Apple. Bar plot indicates daily COVID-19 cases. Notably, the data suggests that people in Japan and San Francisco Bay Area collaborated with “stay-at-home” measures from the end of February, which might have significantly reduced the expansion of SARS-CoV-2 infections after late March 2020.

References

1. Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. *Nature* 2020.
2. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* 2020.
3. Coronaviridae Study Group of the International Committee on Taxonomy of V. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. *Nat Microbiol* 2020.
4. <https://www.niid.go.jp/niid/images/epi/corona/2019nCoV-02-200420.pdf>.
5. <https://www.gisaid.org/epiflu-applications/next-hcov-19-app/>.
6. <https://covidgenomics.org/>.
7. <https://www.cogconsortium.uk/>.
8. <https://doi.org/10.1101/2020.05.06.080119>.
9. <https://doi.org/10.1101/2020.05.12.20099929>.
10. <https://doi.org/10.1101/2020.05.29.123612>.
11. Gudbjartsson DF, Helgason A, Jonsson H, et al. Spread of SARS-CoV-2 in the Icelandic Population. *N Engl J Med* 2020.
12. Deng X, Gu W, Federman S, et al. Genomic surveillance reveals multiple introductions of SARS-CoV-2 into Northern California. *Science* 2020.
13. Shirato K, Nao N, Katano H, et al. Development of Genetic Diagnostic Methods for Novel Coronavirus 2019 (nCoV-2019) in Japan. *Jpn J Infect Dis* 2020.
14. Jung YJ, Park G-S, Moon JH, et al. Comparative analysis of primer-probe sets for the laboratory confirmation of SARS-CoV-2. *bioRxiv* 2020.
15. ARTIC Network protocol. <https://articnetwork/ncov-2019>.
16. <https://www.biorxiv.org/content/10.1101/2020.03.10.985150v3>
17. <https://www.biorxiv.org/content/10.1101/2020.03.10.985150v3>.
18. Coil D, Jospin G, Darling AE. A5-miseq: an updated pipeline to assemble microbial genomes from Illumina MiSeq data. *Bioinformatics* 2015; **31**(4): 587-9.
19. Katoh K, Standley DM. MAFFT multiple sequence alignment software version 7: improvements in performance and usability. *Mol Biol Evol* 2013; **30**(4): 772-80.
20. Clement M, Posada D, Crandall KA. TCS: a computer program to estimate gene genealogies. *Mol Ecol* 2000; **9**(10): 1657-9.

- 385 21. <https://www.apple.com/covid19/mobility>.
- 386 22. <https://www.niid.go.jp/niid/ja/diseases/ka/corona-virus/2019-ncov.html>.
- 387 23. <https://github.com/nytimes/covid-19-data>.
- 388 24. <https://ourworldindata.org/coronavirus-source-data>.
- 389 25. <https://doi.org/10.1101/2020.05.21.109322>.
- 390 26. Sekizuka T, Kuramoto S, Nariai E, et al. SARS-CoV-2 Genome Analysis of Japanese
391 Travelers in Nile River Cruise. *Front Microbiol* 2020; **11**: 1316.
- 392